ENMD-2076 (ENMD2076) is a novel,potent and orally bioactive inhibitor of multikinase including Aurora A and Flt3 with potential antitumor activity.

TCS 7010 (Aurora A Inhibitor I; TCS-7010 ) is a novel, potent, and highly selective inhibitor of Aurora A kinase-AAK with potential antitumor activity.

JNJ-7706621 (JNJ7706621) is novel and potent pan-CDK (cyclin-dependent kinases) inhibitor and also an Aurora-A and Aurora-B inhibitor with potential antitumor activity.

MK-8745 is a novel, potent, specific and selective Aurora A inhibitor with potential antitumor activity.

Phthalazinone pyrazole is a potent, selective, and orally bioavailable inhibitor of Aurora A kinase (IC50 = 31 nM).

Aurora kinase inhibitor III, a 2,4-dianilinopyrimidine compound, is a novel, potent, highly selective, cell-permeable and ATP-competitive inhibitor of aurora related kinase (ARK) with IC50 of 42 nM for Aurora A kinase.

Aurora kinase inhibitor II is a novel , potent selective and ATP-competitive inhibitor of Aurora kinases.

Ilorasertib (also known as ABT-348) is a potent, novel, orally bioavailable and ATP-competitive multi-kinase inhibitor with IC50s for inhibiting binding Aurora B (7 nM), C (1 nM), and A (120 nM), and also inhibits RET tyrosine kinase, PDGFRβ, and Flt1 with IC50s of 7 nM, 3 nM and 32 nM.

Barasertib phosphate (also known as AZD-1152), the phosphate salt of Barasertib, is an investigational, highly selective, orally bioavailable small-molecule Aurora B inhibitor (IC50 = 0.37 nM in a cell-free assay) with anticancer activity.

SCH-1473759 (SCH1473759) is a novel, potent and selective aurora inhibitor with anticancer effects.